Table 2 Median 3-year overall survival (OS)/disease free survival (DFS) and median OS/DFS in months in previously diagnosed AEL patients depending on subtypes and cytogenetic risk group (MRC and IPSS criteria)
Parameter | Median 3-year OS | Median OS (Months) | P | Median 3-year DFS | Median DFS (Months) | P |
|---|---|---|---|---|---|---|
Subtype | ||||||
MDS | 56% | 44.6 | 0.563 | 75.1% | n.r. | 0.538 |
AML | 64.4% | n.r. | 60.7% | n.r. | ||
Cytogenetics | ||||||
Intermediate MRC category | 62.2% | n.r | <0.0001 | 71.5% | n.r | 0.008 |
Unfavorable MRC category | 12% | 5.03 | 25% | 5.3 | ||
Good IPSS category | 56.9% | n.r | 0.045 | 69.3% | n.r | 0.099 |
Intermediate IPSS category | 75% | n.r | 85.7% | n.r | ||
Adverse IPSS category | 13.3% | 11.8 | 25% | 5.33 | ||